Kellie Ryan

AstraZeneca (France) — France

Medicine · Health Sciences

22h-index1.5kcitations71works2.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(23), Lung Cancer Treatments and Mutations(12), Lymphoma Diagnosis and Treatment(10), Lung Cancer Diagnosis and Treatment(10), Antibiotic Use and Resistance(6)

Publications71 total

Patient-Centered Real-World Evidence Framework for Oncology Product Development
Cancer Investigation·2025
Abstract P2-12-20: A Real-World Study of the Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in HER2-low Metastatic Breast Cancer (mBC) among Racial and Ethnic Minorities and Older Populations in the United States
Clinical Cancer Research·2025
27 Pancreatic solid pseudopapillary tumor in a patient with newly diagnosed invasive breast ductal carcinoma
The American Journal of the Medical Sciences·2025
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)
Leukemia & lymphoma/Leukemia and lymphoma·2024Open Access
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study
Blood Advances·2024· 11 citedOpen Access
Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences
Targeted Oncology·2023· 4 citedOpen Access
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
Blood Advances·2023· 27 citedOpen Access
Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL)
Expert Review of Pharmacoeconomics & Outcomes Research·2023· 2 cited
Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States
Expert Review of Pharmacoeconomics & Outcomes Research·2023· 8 citedOpen Access
Health disparity in use of novel agents for first-line therapy in Black and White patients with chronic lymphocytic leukemia in the Department of Veterans Affairs
Journal of Managed Care & Specialty Pharmacy·2023· 9 citedOpen Access
Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Blood·2022· 2 cited
Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia
Blood·2022· 3 cited
Shift in First-Line Therapies for United States Veterans Health Administration (VHA) Patients with Chronic Lymphocytic Leukemia (CLL) from 2014 to 2021
Blood·2022· 2 cited
Clinician and Patient Factors Influencing Treatment Decisions in Front-Line Chronic Lymphocytic Leukemia: A Qualitative Research Study
Blood·2022
Real-World Ibrutinib dose Reductions, Holds and Discontinuations in Chronic Lymphocytic Leukemia
Future Oncology·2021· 26 citedOpen Access
Uptake of Novel Agents (NAs) As First-Line Treatments for Black and White Patients with Chronic Lymphocytic Leukemia (CLL) in the Veterans Health Administration (VHA): A Retrospective Cohort Study
Blood·2021
Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax
Blood·2021
EC3 Economic Burden of Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia Treated with Novel Agents
Value in Health·2021
Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System
Leukemia & lymphoma/Leukemia and lymphoma·2021· 11 cited
Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects
Patient Preference and Adherence·2021· 27 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Hannah Le(6), Caroline Schaefer(5), Svea K. Wahlstrom(5), Maral DerSarkissian(5), Mei Sheng Duh(5), Arthi Chandran(4), Gergana Zlateva(4), Danielle Potter(4), Lindsey E. Roeker(4), Anthony R. Mato(4), Emuella Flood(3), Matthew D. Rousculp(3), Kathleen Beusterien(3), Stan L. Block(3), Matthew C. Hall(3), Parthiv J. Mahadevia(3), Sudeep Karve(3), Pascale Peeters(3), Elisa Baelen(3), Sònia Rojas‐Farreras(3)